The use of neuromuscular blocking agents (NMBAs) early in the development of ARDS has been a strategy of interest for many years. The use of NMBAs with a concomitant deep sedation strategy can increase oxygenation and possibly decrease mortality when used in the early stages of ARDS. The mechanism by which this occurs is unclear but probably involves a combination of factors, such as improving patient-ventilator synchrony, decreasing oxygen consumption, and decreasing the systemic inflammatory response associated with ARDS. The use of NMBA and deep sedation for these patients is not without consequence. This discussion describes the rationale and evidence behind the use of NMBAs in the setting of ARDS.
Introduction
Sedatives, opioids, and neuromuscular blocking agents (NMBAs) are commonly used medications in the ICU. Their administration is meant to achieve comfort and maintain safety in mechanically ventilated patients. Excessive sedation, however, may prolong the length of mechanical ventilation and increase the risk of complications in intubated patients. 1, 2 The dilemma we face in caring for critically ill patients is the balance between maintaining patient comfort while minimizing the adverse outcomes of our therapies. Inherent to the use of mechanical ventilation is a subset of patients who can become asynchronous with the ventilator, particularly when the severity of a patient's illness increases. Appropriate patient-ventilator interaction is of paramount importance. Asynchrony between the patient and the mechanical ventilator can contribute to patient discomfort and dyspnea, 3 increase work of breathing, increase respiratory muscle fatigue, and produce measurement errors in the assessment of breathing frequency and readiness to wean. Difficulties with weaning translate into worse outcomes in the ICU, including prolonged mechanical ventilation time, increased stay in the ICU, increased muscle injury, increased risk of tracheostomy, and even an increase in mortality. [4] [5] [6] [7] [8] Optimizing patient-ventilator interaction to minimize asynchrony can require the use of larger doses of sedatives and NMBAs, a practice that is inconsistent with our goals of minimizing sedation.
Management of ARDS remains a challenge in the ICU. Despite what we have learned regarding lung-protective ventilation strategies with low tidal volumes, ARDS still carries a high mortality rate. 9, 10 Strategies such as prone positioning [11] [12] [13] [14] and targeting higher than traditional PEEP to achieve an open lung have some limited evidence of therapeutic effectiveness. 15, 16 The use of NMBAs early in the development of ARDS has been a strategy of interest for the last decade. There is convincing evidence that the use of NMBAs with a concomitant deep sedation strategy can increase oxygenation and possibly decrease mortality when used in the early stages of ARDS. [17] [18] [19] The mechanism by which this occurs is unclear but probably involves a combination of factors, such as improving patient-ventilator synchrony, decreasing oxygen consumption, and decreasing the systemic inflammatory response associated with ARDS. 18, 20, 21 The use of NMBAs and subsequently deep sedation for these patients is not without consequence.
The following discussion will describe the rationale and evidence behind the use of NMBAs and the potential risks involved in the setting of ARDS.
Pro: NMBAs May Improve Survival in ARDS
Mechanisms by Which NMBAs Improve Survival in ARDS ARDS continues to be a major source of morbidity and mortality. It affects approximately 190,000 patients annually in the United States and is associated with a mortality estimated at Ͼ40%. 10 ARDS is an inflammatory disease process characterized by diffuse bilateral pulmonary edema, decreased lung compliance, and hypoxemia. 6 The only well-established therapy for ARDS is the supportive use of lung-protective mechanical ventilation strategies aimed at minimizing further lung damage by limiting tidal volumes and decreasing mean airway pressures. 9 Until recently, there has not been any specific pharmacologic therapy shown to improve mortality or outcomes in ARDS. In a randomized controlled trial of 340 subjects with severe ARDS, however, Papazian et al in the ACURASYS trial 18 reported that the use of NMBAs early in the course of treatment decreased the duration of mechanical ventilation and improved survival. The major causes of death in patients with ARDS are severe hypoxemia and multi-system organ failure, secondary to infection, sepsis, hemodynamic instability, and ventilator-induced lung injury. 6 It is important to examine how the use of NMBAs can influence this pathophysiology.
Reduced pulmonary compliance and diffusion limitations secondary to edema and inflammation at the alveolar-capillary level, which result in hypoxemia and hypercarbia, are hallmarks of ARDS. Without paralysis, hypoxemia and hypercarbia stimulate respiratory drive, which can lead to increased tidal volumes, active exhalation, and patient-ventilator asynchrony. 6 With improved patient-ventilator synchrony with the administration of NMBAs, tidal volumes can be tightly regulated, thus decreasing the barotrauma and volutrauma caused by overdistention of alveoli from high tidal volume ventilation. Limiting active exhalation with paralysis also allows for better control over PEEP, thereby reducing atelectotrauma or injury due to repetitive opening and closing of lung units. Patient-ventilator asynchrony can be caused by several different mechanisms, including ineffective inspiratory effort during the exhalation cycle, double-triggering (breath-stacking), inappropriate cycling, and aborted inspiration. 8 These asynchronies occur when patients are more interactive with the ventilator and oftentimes air-hungry, a common scenario for a patient with ARDS. The result of asynchrony is ineffective ventilation and increased airway pressures, both of which are detrimental to a lung-protective mechanical ventilation strategy. In an observational study, Blanch et al 8 measured an asynchrony index in 50 subjects mechanically ventilated on various modes of mechanical ventilation. The asynchrony index was based on the number of asynchronous events a subject had with the ventilator in a given hour. They reported that an asynchrony index of Ͻ10% (compared with those Ͼ10%) was associated with decreased ICU and hospital mortality and a trend toward shorter duration of mechanical ventilation. 8 NMBAs can eliminate this asynchrony by removing patient effort and allowing the ventilator to control the triggering and cycling of breaths.
Severe hypoxemia contributes to the mortality associated with ARDS. NMBAs improve oxygenation in ARDS. In a randomized controlled trial of 56 subjects with ARDS, Gainnier et al 17 examined the effects of NMBAs on oxygenation parameters. Compared with placebo, subjects who received NMBAs for 48 h early in the course of ARDS had significantly improved P aO 2 /F IO 2 after 48 h. This effect persisted for several days beyond discontinuation of the NMBA. The NMBA group also had faster weaning of PEEP, indicating improved lung compliance at the end of the 5-d study period. 17 A separate randomized trial by Forel et al 21 reported similar improvements in oxygenation with the use of NMBAs in early ARDS. 21 The mechanism for improved oxygenation remains unclear. It may be a result of improved ventilation-perfusion relationships that occur with the initiation of muscle paralysis and the ability to maintain consistent levels of PEEP throughout all lung fields. 6 There is some evidence that muscle paralysis or even deep sedation with a Ramsay score of Ͻ6 reduces the oxygen consumption by ventilatory muscles. [22] [23] [24] The reduction in oxygen consumption might decrease demand for oxygen delivery and carbon dioxide removal, ultimately resulting in decreased cardiac output and decreased pulmonary blood flow, which then may minimize the edema seen at the alveolar-capillary level in ARDS. What is interesting to note is that for both the Gainnier et al 17 and Forel et al 21 trials, the improvement in oxygenation persisted throughout the 5-d study period, well beyond the 48 h of muscle paralysis, 17, 21 which suggests that the reduction in oxygen consumption cannot be the primary mechanism of improved oxygenation.
Another mechanism in which NMBAs could improve survival in ARDS may involve an anti-inflammatory effect. The lungs of a patient with ARDS are subject to overinflation and overstretching by mechanical ventilation, which may produce biotrauma, a regional and systemic inflammatory response that may generate or amplify multi-system organ failure. Causes of biotrauma include repetitive opening and closing of atelectatic lung units, surfactant alterations, loss of alveolar-capillary barrier, and bacterial translocation. 25 In animal models of ARDS, Imai et al 26 found that high tidal volume low PEEP mechanical ventilation can increase inflammatory markers and rates of apoptosis in the kidney and small intestine, which suggested a multi-system organ response to varying strategies of mechanical ventilation. The trial by Forel et al 21 of NMBAs in ARDS evaluated inflammatory cytokine levels in the serum and bronchoalveolar lavage samples of subjects randomized to NMBA versus placebo. They reported that bronchoalveolar lavage levels of interleukin (IL)-8, IL-6, and IL-1B and serum levels of IL-6 and IL-1B were lower in the NMBA group at 48 h after randomization. 21 One explanation of the efficacy of NMBAs in decreasing this inflammatory response is that paralysis induces greater homogeneity of the distribution of PEEP and tidal volume. This would reduce de-recruitment of dependent lung areas and minimize the repetitive opening and closing of atelectatic lung units and perhaps limit inflammatory mediator release normally associated with de-recruitment and atelectasis. 21 Cisatracurium may also have a primary receptor-mediated anti-inflammatory effect on cells. 6 The clinical importance of this effect, however, remains unclear at this point.
Outcomes of NMBA Administration in Early ARDS
So the question remains: If NMBAs can decrease inflammation, improve oxygenation, and improve patientventilator asynchrony in patients with ARDS, does this translate to improved outcomes in the ICU? To date, Papazian et al 18 have performed the largest randomized controlled study, the ACURASYS trial, to help answer this question. They conducted a multi-center, placebocontrolled, double-blind study of 340 subjects with ARDS (defined as a P aO 2 /F IO 2 of Ͻ150 with a PEEP of Ն5 cm H 2 O and a tidal volume of 6 -8 mL/kg ideal body weight) to determine whether a short period of treatment with cisatracurium early in the course of severe ARDS would improve clinical outcomes. The baseline characteristics between the treatment and control arms were similar with the exception that the cisatracurium group had a lower baseline mean P aO 2 /F IO 2 ratio compared with placebo, 106 versus 115 (P ϭ .03), respectively. The primary end point was 90-d mortality. Using the Cox multivariate regression model and adjusting for baseline P aO 2 /F IO 2 , plateau pressure, and Simplified Acute Physiology Score II, they found that the hazard ratio for death at 90 d in the cisatracurium group, as compared with placebo, was 0.68 (95% CI 0.48 -0.98, P ϭ .04). In crude analysis, the 90-d mortality rate in the cisatracurium group was 31% (95% CI 25-38%) compared with 40% in the placebo group (95% CI 33-48%), P ϭ .08. The improved survival in the cisatracurium group was limited to the two thirds of subjects presenting with a P aO 2 /F IO 2 of Ͻ120.
Secondary outcomes evaluated were ventilator days, ICU stay, number of organ or system failures, barotrauma, ICUacquired paresis, and muscle strength as evaluated by the Medical Research Council scale. The cisatracurium group had more ventilator-free days than the placebo group during the first 28 and 90 d (10.6 d vs 8.5 d, P ϭ .04, 53.1 d vs 44.6 d, P ϭ .03) and more days spent outside of the ICU within the first 90 d compared with placebo (47.7 vs 39.5, P ϭ .03). The cisatracurium group had a decrease in the number of days without organ failure compared with placebo when assessing coagulation abnormalities, hepatic failure, and renal failure, but these differences were not statistically significant. Pneumothorax occurred in a larger percentage in the placebo group (11% vs 4% in the cisatracurium group, P ϭ .04). Before the development of pneumothorax in either study group, none of the subjects had an elevated plateau pressure necessitating changes in management. The incidence of ICU-acquired paresis as evaluated by the Medical Research Council scale on day 28 or at time of ICU discharge did not differ significantly between the 2 study groups.
Con: Early Use of NMBAs May Not Be Indicated
Routinely for ARDS Patients
Criticisms of ACURASYS Trial
Although the results of the ACURASYS trial are very encouraging, we must consider that, although the trial included 340 subjects, it is statistically under-powered to evaluate mortality. According to the authors, 885 subjects should be needed to achieve 80% statistical power. 18 In addition, the survival benefit was limited to those subjects with a P aO 2 /F IO 2 of Ͻ120, further limiting statistical strength. The study also has not been reproduced in other multicenter randomized trials and has not been attempted with other NMBAs besides cisatracurium.
Critics of the ACURASYS trial argue that if one of the major benefits of NMBAs is the improvement in patient-ventilator synchrony, then it would have been advantageous for the study to monitor and assess patient-ventilator interactions to determine a causal relationship. Hence, the relationship remains speculative. One can argue that the incidence of patient-ventilator asynchrony may not be as high as expected in the ARDS population. 27 Epstein 28 reported that only 30% of ARDS subjects suffered from ineffective ventilator triggering compared with subjects with respiratory failure from other mechanisms. 27, 28 If the incidence of asynchrony is low, then intervention with NMBAs may not be advantageous. If asynchrony is problematic in a patient with ARDS, then other non-pharmacologic interventions might effectively improve patient-ventilator dynamics.
For example, Chanques et al, 29 evaluating mechanically ventilated subjects in the ICU, reported that 26% exhibited severe breath-stacking asynchrony with a mean asynchrony index of 44%. Management options included no intervention, increasing sedation/analgesia, or making a ventilator adjustment. Compared with baseline, the decrease in asynchrony index was greater after adjusting ventilator settings than after increasing sedation/analgesia (P Ͻ .001) or deciding to tolerate asynchrony (P Ͻ .001). The transition to pressure-support ventilation and increased inspiratory time were independently associated with a reduction in asynchrony index. 29 In the ACURAYS trial, all subjects were mechanically ventilated in a volume assist-control mode, and this mode was not adjusted for the sake of blinding. All subjects were sedated to a Ramsay score of 6 (no response to glabelar tap) before the initiation of treatment. If there were sustained episodes of elevated end-inspiratory plateau pressure Ͼ 32 cm H 2 O, which can occur during episodes of asynchrony, then tidal volume and PEEP levels were adjusted, sedation was increased, and openlabel cisatracurium was bolused, but the mode of ventilation was never changed. 18 It is conceivable that inadequate management of asynchrony in the placebo group could have predisposed to worse outcomes.
Another concern in the ACURASYS trial is that depth of neuromuscular blockade was not monitored. The use of a train-of-four peripheral nerve simulator is generally considered a standard of care for managing and titrating the effect of neuromuscular blockade. Due to obvious blinding considerations, monitoring of train-of-four was not done in this study. As a result, adequacy and duration of neuromuscular blockade in the treatment group can be called into question. There are reports of tachyphylaxis and resistance to neuromuscular blockade in critically ill patients. 30, 31 Thus, it is possible that the benefits observed in the cisatracurium group were independent of neuromuscular blockade.
Risks Associated With the Use of NMBAs
There are inherent risks to the use of NMBAs in patients in the ICU. Unrecognized ventilator disconnections can quickly lead to hypoxemia and hypercarbia and cause cardiopulmonary collapse. Inadequate sedation and analgesia in a paralyzed patient can cause extreme psychologic distress. As an example, Nelson et al 32 investigated the relationship between the use of NMBAs during acute lung injury and the quality of life of survivors in a retrospective study of 24 subjects questioned after treatment in the ICU. Post-traumatic stress disorder symptoms were positively correlated with days of sedation and days of NMBA use but not with severity of illness. The inhibition of a cough reflex can lead to poor secretion clearance and mucus plugging that can cause increased airway pressures and hypoxemia if not effectively addressed. Patients are more at risk for corneal abrasion and ulceration given their inability to blink; thus, artificial tears should be applied intermittently, and eyes should be taped shut to prevent drying. During the period of paralysis, neurologic evaluation is not possible; therefore, recognition of neurologic deterioration during this time will be delayed.
Prolonged paralysis after discontinuation of NMBAs, defined as an increase in the time to recovery of 50 to 100% longer than predicted by pharmacologic parameters, is a problem encountered specifically after prolonged infusions on NMBAs and more commonly reported in the steroid-based NMBAs, including pancuronium, vecuronium, and rocuronium. [33] [34] [35] This is primarily due to the accumulation of NMBAs or their metabolites. 36 Steroidbased NMBAs undergo extensive hepatic metabolism, producing active drug metabolites, some of which can be 80% as potent as the parent compound. These active drug metabolites are renally excreted; thus, accumulation of parent drug and active metabolites is enhanced in the setting of hepatic and/or renal dysfunction. 36 Drug-drug interactions can also potentiate depth of motor blockade and may prolong recovery. Drugs that are implicated include local anesthetics, aminoglycoside antimicrobials, calcium channel blockers, magnesium, diuretics, lithium, and antiarrhythmics, including procainamide and quinidine. 36 Whether NMBAs contribute to ICU-acquired weakness is still under debate. What is known is that critical illness polyneuropathy and critical illness myopathy are responsible for significant morbidity in critically ill patients. Research for the last 2 decades has shown that critical illness polyneuropathy and myopathy can affect up to 50% of the ICU population. They present as limb and respiratory mus-cle weakness and, even with improvement, can cause varying degrees of disability after discharge from the hospital, from subtle weakness with limitation in exercise tolerance to profound disability. 37, 38 Sepsis, systemic inflammatory response syndrome, and multi-organ failure are risk factors for critical illness polyneuropathy and myopathy. A systematic review of published work showed evidence of critical illness polyneuropathy and myopathy in 46% (95% CI 43-49) of adult ICU subjects who had lengthy mechanical ventilation, sepsis, or multi-organ failure. 39 Risk factors have been discussed in the literature. In a prospective cohort study of mechanically ventilated ICU subjects, De Jonghe et al 40 identified independent risk factors for the development of ICU-acquired weakness, which include female sex, multiple organ dysfunctions, duration of mechanical ventilation, and administration of corticosteroids. Duration of vasopressor support, duration of ICU stay, hyperglycemia, low serum albumin, and neurological failure have also been identified as risk factors. 41, 42 With respect to NMBAs, the literature is contradictory. In a cohort study of 73 septic subjects with multi-organ dysfunction syndrome requiring mechanical ventilation, Garnacho-Montero et al 43 reported that 63% of subjects developed critical illness polyneuropathy as diagnosed by electrophysiologic studies. Of the subjects diagnosed with critical illness polyneuropathy, 18% of them received NMBAs during their ICU stay. After multivariate analysis, they determined that the use of NMBAs was independently associated with the development of critical illness polyneuropathy. 43 Griffiths and Hall 44 reported that simultaneous use of NMBAs and corticosteroids could be associated with muscle weakness, whereas NMBA use alone was not identified as an independent risk factor. Other studies, however, have not been able to support the relationship between NMBAs and development of critical illness polyneuropathy and myopathy. 18, 40, 42, 45, 46 What we have learned from the literature is that immobility has profound effects on skeletal muscle and is a risk factor for muscle weakness during critical illness. 38 The use of NMBAs can certainly increase the duration of immobility, but the evidence to implicate it as an independent risk factor for prolonged disability is not definitive.
The Appropriate Use of NMBAs in ARDS Patients
The choice of NMBA and how it is utilized is critical. The ideal neuromuscular blocker would have a titratable effect, rapid onset and offset of paralysis to allow for neurological assessments, no adverse hemodynamics or physiologic adverse effects, hepatic and renal functionindependent elimination, inactive metabolites, and reasonable cost. The available NMBAs in the United States are pancuronium, vecuronium, rocuronium, atracurium, and cisatracurium (Table 1) . Since the combination of longterm high-dose corticosteroids and prolonged NMBAs, particularly the steroidal NMBAs, could increase the likelihood of developing an acute myopathy, 34, 44 attempts should be made to avoid the steroidal NMBA (vecuronium, rocuronium, pancuronium) infusions. Vecuronium has active metabolites. Pancuronium, vecuronium, and rocuronium undergo hepatic metabolism and renal elimination to varying degrees. Both atracurium and pancuronium have adverse effects. Both atracurium and cisatracurium undergo Hoffman elimination, an organ-independent spontaneous degradation, which is temperature-and plasma pHdependent. Cisatracurium is free of active metabolites and adverse effects, making it an appealing NMBA. To date, no study has definitively compared the use of different NMBAs in ARDS subjects.
In addition to the choice of NMBA, the method of utilization of NMBA can impact outcomes ( Table 2 ). The use of NMBAs in ARDS should be rare, but when used, attempts should be made to minimize their dose and duration. 47 Initiation and duration should be limited to the first 48 h in severe ARDS with discontinuation as soon as possible. In an effort to limit NMBA dosing, depth of blockade should be guided by peripheral neuromuscular monitoring. The train-of-four, obtained from the peripheral neuromuscular monitor, goal is to achieve and maintain 1 to 2 twitches. In a prospective, randomized singleblind trial of 77 critically ill subjects receiving continuous NMBA, dosing guided by clinical response versus peripheral neuromuscular monitoring resulted in less drug per hour and total drug used. Subjects who underwent peripheral neuromuscular monitoring recovered neuromuscular Hofmann elimination ϭ spontaneous degradation in the plasma, independent of organ function function (relative risk 1.89) and spontaneous ventilation (relative risk 2.27, 95% CI of 1.23-4.21, P ϭ .019) faster than control subjects. 48 When NMBAs are used, ensure adequate sedation and analgesia before neuromuscular blockade, frequent turning and pressure point padding, elevation of the head of bed Ͼ30 degrees, suctioning to clear secretions, close supervision and avoidance of ventilator disconnections, and application of eye care to avoid corneal abrasions (Table 3) .
Summary
Convincing evidence exists that suggests the use of NMBAs in the setting of ARDS can have a positive impact on mortality, ventilator days and ICU length of stay. The most promising application has been with its early use (within 48 h of development of ARDS), and in those patients with severe disease (P aO 2 /F IO 2 Ͻ 120). Potential mechanisms by which this occurs are multifactorial and include improving patient-ventilator synchrony, improving oxygenation, decreasing oxygen consumption, and decreasing the systemic inflammatory response associated with ARDS. The application of NMBAs, and the deep sedation that is required with their use, however, is certainly not without consequence. Some of the risks associated with this practice include prolonged mechanical ventilation due to excessive sedation, prolonged paralysis after discontinuation of NMBAs, development of critical illness myopathy and neuropathy, development of corneal abrasions and ulcerations, and risk of apnea with unrecognized ventilator disconnections. As clinicians, we continuously have to balance the risks and benefits associated with our therapies and adjust our treatment strategies. If NMBAs are used in the setting of severe ARDS, we recommend limiting their duration of use to 48 h, avoiding administration of corticosteroids with steroidal NMBAs, and titrating their dosage according to physical signs and routine use of peripheral nerve monitoring. Hurford: Not to my knowledge.
Berra:
There was an anti-inflammatory study 2 in a septic animal model.
Kacmarek:
I thought there were a couple references in Art's editorial? 3 To the anti-inflammatory effects, at least in some models?
Kallet: I was also interested in the high dose of cisatracurium and the antiinflammatory effects. If it's not that, one thing that comes to mind is possibly inhibiting pro-inflammatory mediator release from the respiratory muscles. Compared to other skeletal muscles, the diaphragm has a higher baseline production of pro-inflammatory mediators. 4 I'm not sure why, but it does. I was looking up some articles on athletes and pro-inflammatory mediator release, which doesn't directly apply, but strenuous muscular exercise produces a substantial amount of pro-inflammatory mediators. 5, 6 So someone rigid, struggling, and breathing like crazy, it might be that we take that out of the equation. In fact, it's been shown that increased respiratory muscle loads cause an intense inflammatory response. 7 Bill, could you address this? Do you think the mortality difference would be seen early on? Because the separation in mortality is around 3 weeks. That's kind of hard to interpret; it's not what I would expect to see using early paralysis in ARDS.
Marini: I have exactly the same question . . . and maybe a hypothesis to explain that observation. Could it be that we are programmed by evolution to die when we get this sick? In other words, from an evolutionary standpoint because somebody this sick is not likely to survive and might be a little weaker than the others, take them out of the reproduction circuit. Our body systems might not be geared to respond to severe, life-threatening stress in a constructive way. So, if there were a catastrophic positive feedback loop that was interrupted by taking control, the mortality difference might be expected to emerge some time after the neuromuscular blockade was used. In most studies of ARDS, subjects tend to die in the 2-3 week window. But it's rare to have a study where everybody's mortality risk is identical for the first week to 10 d and then the groups separate sharply at day 15 or 16. Is there some signal we're interrupting early on? In other words, do we slow the freight train of dysfunction brought on by the early excessive response -and by doing that affect mediators, anti-inflammatory effects and all that kind of stuff? Maybe any anti-inflammatory property of cisatracurium is dose-related, too. I don't think that we know that.
Hurford: All excellent comments and certainly I don't know the answers. The question about the antiinflammatory effect of cisatracurium is that it would be very bizarre that this would be the one anti-inflammatory of the last 3 decades that is so effective after the use of general inflammatory drugs such as high-dose steroids and such have not had that benefit. I remain unconvinced. But there's no question that it could be. It's very difficult to prove or disprove and to tease that out.
Kacmarek: Art talks in his editorial 3 about recent articles dealing with asynchrony and all the issues associated with it. In those articles, subjects don't die early, either. Like in Lluís Blanch's recent study 8 death was not immediate, it was weeks later when these subjects were dying. So maybe breaking that cycle that you see in early severe ARDS where patients are really fighting the ventilator, they have significant hemodynamic issues and we don't have time or capability to stabilize them, paralyzing them for that period of time perhaps minimizes injury and allows for more rapid stabilization.
Hurford:
The other way to think about that is we are pretty good at keeping people alive if we want to. So, as that cycle progresses on to renal failure, coagulopathy, liver failure, coma, that takes some time. And that final mode of death is usually limitation of further support or aggressive therapy rather than a catastrophic event.
Kallet: Dale Needham did a retrospective study 9 about ARDS Net management in the Baltimore area and found that the degree of adherence to lung-protective ventilation actually affected mortality 1-2 y out from the advent of ARDS. Which is not really explained, but it suggests that something happens very early on that we don't know about. In doing the paper on hyperoxia for this presentation, there were some studies on exposure to hyperoxia in neonates showing that it has an impact on disease development many years later in life. Maybe some genetic alteration occurs that gets turned on or can't be turned off. It will be intriguing to see what happens in the next 20 years when they do more research on that. Obviously something is going on.
Kacmarek: Let me ask a question. Do we need to paralyze for 48 h or do we need to paralyze until we establish stability? And how frequently do we need to reassess and lighten it up or reverse the paralysis and determine whether or not we need to keep going?
Hurford: I don't know.
Kacmarek:
That's not a good answer!
